BioRestorative Therapies (BRTX) announced that the European Patent Office has issued a Notice of Allowance for a new patent application covering key aspects of the company’s allogeneic, off-the-shelf ThermoStem metabolic disease platform. Claims granted under the new patent cover a method of making a non-naturally occurring three-dimensional brown adipose derived stem cell aggregate.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRTX: